Methylene Blue Improves the Hepatopulmonary Syndrome
Authors: Peter Schenk, Stephan Lehr, Christian Müller
Journal: Annals of Internal Medicine (2001)

Letters4 September 2001Methylene Blue Improves the Hepatopulmonary SyndromePeter Schenk, MD, Stephan Lehr, and Christian Müller, MDPeter Schenk, MDUniversity of Vienna; 1090 Vienna, Austria (Schenk), (Lehr), (Müller)Search for more papers by this author, Stephan LehrUniversity of Vienna; 1090 Vienna, Austria (Schenk), (Lehr), (Müller)Search for more papers by this author, and Christian Müller, MDUniversity of Vienna; 1090 Vienna, Austria (Schenk), (Lehr), (Müller)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-5-200109040-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Drs. Groneberg and Fischer for their interest and Dr. Fallon (1) for his excellent editorial. In our study, no significant change was seen in hepatic or renal function before and after methylene blue infusion, respectively (total bilirubin level, 183 ± 202 µmol/L [10.7 ± 11.8 mg/dL] vs. 180 ± 188 µmol/L [10.5 ± 11 mg/dL] [P > 0.2]; serum albumin level, 289 ± 43 g/L vs. 299 ± 38 g/L [P = 0.17]; prothrombin time, 37.7 ± 10 seconds vs. 38 ± 9 seconds [P > 0.2]; serum creatinine concentration, 115 ± 71 µmol/L [1.3 ± 0.8 mg/dL] vs. 115 ± 62 ...References1. Fallon MB. Methylene blue and cirrhosis: pathophysiologic insights, therapeutic dilemmas [Editorial]. Ann Intern Med. 2000;133:738-40. [PMID: 11074907] LinkGoogle Scholar2. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest. 1993;104:515-21. [PMID: 8101797] CrossrefMedlineGoogle Scholar3. Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995;21:1027-31. [PMID: 8750129] CrossrefMedlineGoogle Scholar4. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, et al . Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23:259-64. [PMID: 7532559] CrossrefMedlineGoogle Scholar5. Andresen M, Dougnac A, Díaz O, Hernández G, Castillo L, Bugedo G, et al . Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care. 1998;13:164-8. [PMID: 9869542] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Vienna; 1090 Vienna, Austria (Schenk), (Lehr), (Müller) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMethylene Blue Improves the Hepatopulmonary Syndrome Peter Schenk , Christian Madl , Shahrzad Rezaie-Majd , Stephan Lehr , and Christian Müller Methylene Blue Improves the Hepatopulmonary Syndrome David A. Groneberg and Axel Fischer Metrics Cited byLife-Threatening Serotonin Syndrome Due to Methylene Blue–Citalopram Interaction 4 September 2001Volume 135, Issue 5Page: 380-381KeywordsMethylene blueProspective studiesProthrombin timePulmonary arteriesPulmonary vascular resistanceSalivaSerum albuminShockSystemic vascular resistanceUrine ePublished: 4 September 2001 Issue Published: 4 September 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...